ZIMLAB2024-10-012024-12-31 ZIMLAB2024-10-012024-12-31 ZIMLAB2024-10-012024-12-31in-bse-fin:OneOperatingExpenses01Member ZIMLAB2024-10-012024-12-31in-bse-fin:FourOperatingExpenses01Member ZIMLAB2024-12-31 ZIMLAB2024-10-012024-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member ZIMLAB2024-10-012024-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member ZIMLAB2024-10-012024-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member ZIMLAB2024-10-012024-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 541400 ZIMLAB NOTLISTED Zim Laboratories Limited Equity 2024-04-01 2025-03-31 2025-02-10 2025-02-03 INR Lakhs Third quarter 15:00:00 19:15:00 2025-02-10 2025-02-10 Not applicable Single segment Pharmaceutical Industry 2024-10-01 2024-12-31 Unaudited Consolidated 963303000.00 17546000.00 980849000.00 398754000.00 24865000.00 -11078000.00 144747000.00 27330000.00 48807000.00 290387000.00 923812000.00 57037000.00 0.00 57037000.00 7476000.00 9553000.00 17029000.00 0.00 40008000.00 0.00 0.00 0.00 0.00 40008000.00 2825000.00 42833000.00 40008000.00 0.00 42833000.00 0.00 487258000.00 10 0.82 0.82 0.00 0.00 0.82 0.82 0.00 0.02 0.03 Notes : 1) The above results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 10 February 2025. There are no qualifications in the limited review report issued for the quarter & nine months ended 31 December 2024. 2) These financial results have been prepared in accordance with the recognition and measurement principles of applicable Indian Accounting Standard ('Ind AS') notified under the Companies (Indian Accounting Standards) Rules, 2015 (as amended), as prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations and guidelines issued by the Securities and Exchange Board of India (SEBI). 3) The Company and its subsidiaries are principally engaged in a single business segment which is pharmaceuticals . Place: Nagpur Anwar S. Daud Date: 10 February 2025 Managing Director Single segment 2024-04-01 2024-12-31 Unaudited Consolidated 2702980000.00 40743000.00 2743723000.00 1064031000.00 82823000.00 49079000.00 444352000.00 84790000.00 148244000.00 771394000.00 2644713000.00 99010000.00 0.00 99010000.00 12708000.00 13497000.00 26205000.00 0.00 72805000.00 0.00 0.00 0.00 0.00 72805000.00 3649000.00 76454000.00 72805000.00 0.00 76455000.00 -1000.00 487258000.00 10 1.49 1.49 0.00 0.00 1.49 1.49 0.00 0.02 0.02 Other Expenses 290387000.00 Other Expenses 771394000.00 Measurements of defind employee benefit plans -1347000.00 Measurements of defind employee benefit plans -4041000.00 -1347000.00 -4041000.00 -392000.00 -1176000.00 Exchange differenaces on translation of foreign operations 3780000.00 Exchange differenaces on translation of foreign operations 6514000.00 3780000.00 6514000.00 0.00 0.00